3sbio inc
Sorrento, 3SBio Enter Immunotherapy Joint Venture In China
The joint venture agreement will develop and commercialize proprietary immunotherapies using chimeric antigen receptor T-cell technology.
3SBio Acquires Zhejiang Wansheng For US$85 Million
The acquisition of Zhejiang Wansheng expands 3SBio's product offerings in the dialysis, diabetes and dermatology markets.
3SBio Licenses DiNonA’s Anti-Leukemia Treatment
3SBio and DiNonA will develop Leukotuximab, an anti JL-1 antibody indicated for the treatment of acute leukemia.
3SBio & Selecta To Develop Non-Immunogenic Gout Drug
By combining pegsiticase with Selecta's synthetic vaccine particle platform, 3SBio hopes to develop an anti-gout drug that will not be affected by drug resistance.
3SBio To Develop DJ5 For Progressive Renal Failure
3SBio Inc. has acquired patents for DJ5 to develop DJ5 as a treatment for progressive renal failure in patients with autosomal dominant polycystic kidney disease.
